OBJECTIVE: A considerable fraction of prostate cancers harbor a gene fusion between the androgen-regulated TMPRSS2 and ERG, one of the most frequently over-expressed proto-oncogenes in prostate cancer. Here, we investigated if inherited genetic variation upstream of ERG alters prostate cancer risk and survival. METHODS: We genotyped 21 haplotype tagging SNPs (htSNPs) covering 123 kb of 5'UTR DNA including exon 3 of ERG in 2,760 incident prostate cancer cases and 1,647 controls from a population-based Swedish case-control study (CAPS). Individual SNPs and haplotypes were tested for association with prostate cancer risk and survival. RESULTS: One haplotype-'CTCGTATG' located 100 kb upstream of ERG-was associated with lethal prostate cancer (HR, 1.36; 95% CI, 1.2-1.9, p = 0.006). Carriers of the variant 'T' allele of rs2836626 were diagnosed with higher TNM-stage (p = 0.009) and had an increased risk of prostate cancer-specific death (HR = 1.3; 95% CI, 1.1-1.7, p = 0.009). However, this association did not remain statistically significant after adjusting for multiple testing. We found overall no association between ERG variation and prostate cancer risk. CONCLUSIONS: Genetic variation upstream of ERG may alter prostate cancer stage and ultimately prostate cancer-specific death but it is unlikely that it plays a role in prostate cancer development.
OBJECTIVE: A considerable fraction of prostate cancers harbor a gene fusion between the androgen-regulated TMPRSS2 and ERG, one of the most frequently over-expressed proto-oncogenes in prostate cancer. Here, we investigated if inherited genetic variation upstream of ERG alters prostate cancer risk and survival. METHODS: We genotyped 21 haplotype tagging SNPs (htSNPs) covering 123 kb of 5'UTR DNA including exon 3 of ERG in 2,760 incident prostate cancer cases and 1,647 controls from a population-based Swedish case-control study (CAPS). Individual SNPs and haplotypes were tested for association with prostate cancer risk and survival. RESULTS: One haplotype-'CTCGTATG' located 100 kb upstream of ERG-was associated with lethal prostate cancer (HR, 1.36; 95% CI, 1.2-1.9, p = 0.006). Carriers of the variant 'T' allele of rs2836626 were diagnosed with higher TNM-stage (p = 0.009) and had an increased risk of prostate cancer-specific death (HR = 1.3; 95% CI, 1.1-1.7, p = 0.009). However, this association did not remain statistically significant after adjusting for multiple testing. We found overall no association between ERG variation and prostate cancer risk. CONCLUSIONS: Genetic variation upstream of ERG may alter prostate cancer stage and ultimately prostate cancer-specific death but it is unlikely that it plays a role in prostate cancer development.
Authors: Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira Journal: Neoplasia Date: 2006-10 Impact factor: 5.715
Authors: Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: Sara Lindström; Fredrik Wiklund; Hans-Olov Adami; Katarina Augustsson Bälter; Jan Adolfsson; Henrik Grönberg Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: Rohit Mehra; Scott A Tomlins; Ronglai Shen; Owais Nadeem; Lei Wang; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan; Rajal B Shah Journal: Mod Pathol Date: 2007-03-02 Impact factor: 7.842
Authors: Kristiina Iljin; Maija Wolf; Henrik Edgren; Santosh Gupta; Sami Kilpinen; Rolf I Skotheim; Mari Peltola; Frank Smit; Gerald Verhaegh; Jack Schalken; Matthias Nees; Olli Kallioniemi Journal: Cancer Res Date: 2006-11-01 Impact factor: 12.701
Authors: Daniel J Schaid; Shannon K McDonnell; Katherine E Zarfas; Julie M Cunningham; Scott Hebbring; Stephen N Thibodeau; Rosalind A Eeles; Douglas F Easton; William D Foulkes; Jacques Simard; Graham G Giles; John L Hopper; Lovise Mahle; Pal Moller; Michael Badzioch; D Timothy Bishop; Chris Evans; Steve Edwards; Julia Meitz; Sarah Bullock; Questa Hope; Michelle Guy; Chih-lin Hsieh; Jerry Halpern; Raymond R Balise; Ingrid Oakley-Girvan; Alice S Whittemore; Jianfeng Xu; Latchezar Dimitrov; Bao-Li Chang; Tamara S Adams; Aubrey R Turner; Deborah A Meyers; Danielle M Friedrichsen; Kerry Deutsch; Suzanne Kolb; Marta Janer; Leroy Hood; Elaine A Ostrander; Janet L Stanford; Charles M Ewing; Marta Gielzak; Sarah D Isaacs; Patrick C Walsh; Kathleen E Wiley; William B Isaacs; Ethan M Lange; Lindsey A Ho; Jennifer L Beebe-Dimmer; David P Wood; Kathleen A Cooney; Daniela Seminara; Tarja Ikonen; Agnes Baffoe-Bonnie; Henna Fredriksson; Mika P Matikainen; Teuvo L J Tammela; Joan Bailey-Wilson; Johanna Schleutker; Christiane Maier; Kathleen Herkommer; Josef J Hoegel; Walther Vogel; Thomas Paiss; Fredrik Wiklund; Monica Emanuelsson; Elisabeth Stenman; Björn-Anders Jonsson; Henrik Grönberg; Nicola J Camp; James Farnham; Lisa A Cannon-Albright; William J Catalona; Brian K Suarez; Kimberly A Roehl Journal: Hum Genet Date: 2006-08-25 Impact factor: 4.132